← Back to screener

SAB Biotherapeutics, Inc. SABS

Rank #2342 · Nasdaq · $0.3B market cap
Audited by EisnerAmper L.L.P., no going-concern flag in the latest filing.
Score
23.5
P/E
-7.5
P/B
4.47
ROE
-59.5%
Op. Margin
-3244.9%
Debt Ratio
32%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Weak

P/E -7.5x, P/B 4.47x. Ranks in the top 74% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -59.5%. Ranks in the top 94% of the universe.

Safety ★★★★☆
Excellent

Debt ratio 32%. Ranks in the top 17% of the universe. Under 100% is generally considered a safe level.

Growth ★☆☆☆☆
Poor

Revenue decline of 40.9% year over year. Ranks in the top 97% of the universe.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2020–––$0.0B–1913
2021$0.1B$0.0B$0.0B$0.0B37.2228
2022$0.1B$-0.0B$-0.0B$0.0B-22.0109
2023$0.0B$-0.0B$-0.0B$0.0B-121.051
2024$0.0B$-0.0B$-0.0B$0.0B-1700.686
2025$0.0B$-0.0B$-0.0B$0.1B-3244.932

← See the full screener